Literature DB >> 9462663

Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy.

S Ohguchi1, H Nakatsukasa, T Higashi, K Ashida, K Nouso, M Ishizaki, N Hino, Y Kobayashi, S Uematsu, T Tsuji.   

Abstract

For an approach of gene therapy for hepatocellular carcinoma (HCC), transcriptional regulatory sequence (TRS) of either alpha-fetoprotein (AFP) or albumin has been used for targeting cancer cells. To examine the feasibility of using TRSs of these genes for possible gene therapy of HCCs, the cellular distribution of AFP and albumin gene transcripts was studied in 25 cases of surgically removed human HCCs. AFP gene expression was observed in HCC nodules of 13 cases. The expression in HCC was heterogeneous, and the distribution of the transcripts was mostly sparse and spotty. The higher the serum AFP levels, the larger population of the AFP-expressing HCC cells tended to reflect. In noncancerous liver, a slight AFP expression was found by Northern blot analysis, but the transcripts were not detected in the liver sections. In contrast, albumin expression was found in all HCCs as well as in noncancerous hepatocytes. In HCC, the transcripts for albumin were distributed in cancer cells, and the expression varied with nodules. There were more albumin-expressing cancer cells than the AFP-expressing cells. Albumin expression was retained even in poorly differentiated HCC, although the intensity of the signal was not as strong as in more-differentiated HCCs. Metastatic HCC nodules revealed transcripts for both AFP and albumin genes, and those were clearly recognized in the lung tissue. These results suggest that, for gene therapy for HCCs, neither AFP nor albumin are ideal options for targeting HCC cells. AFP-TRS may be used as a transcriptional regulator in selected cases in which AFP gene expression is observed in the cancer nodules. The serum AFP level appears to be an important indicator in selecting cases. Albumin-TRS in conjunction with retroviral vector might be used in limited cases such as HCCs with no AFP expression. However, careful consideration must be taken, because albumin is constitutively expressed in normal hepatocytes, and AFP-expressing nonmalignant progenitor cells possibly exist.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462663     DOI: 10.1002/hep.510270239

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line.

Authors:  Meng-Sen Li; Ping-Feng Li; Shi-Peng He; Guo-Guang Du; Gang Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

3.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

Review 4.  Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yinli Yang; Bingqing Zheng; Qiuju Han; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

5.  Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocarcinoma cell.

Authors:  Yu-Jun Shi; Jian-Ping Gong; Chang-An Liu; Xu-Hong Li; Ying Mei; Can Mi; Yan-Ying Huo
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

6.  Exploring the key genes and pathways of osteosarcoma with pulmonary metastasis using a gene expression microarray.

Authors:  Zhongju Shi; Hengxing Zhou; Bin Pan; Lu Lu; Zhijian Wei; Linlin Shi; Xue Yao; Yi Kang; Shiqing Feng
Journal:  Mol Med Rep       Date:  2017-09-21       Impact factor: 2.952

7.  Overexpression of miRNA-21 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma Cells via Suppressing SMAD7.

Authors:  Yan Wang; Ping Zhang; Mei Yuan; Xiaojie Li
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 8.  HBV-HCC treatment with mRNA electroporated HBV-TCR T cells.

Authors:  Anthony T Tan; Antonio Bertoletti
Journal:  Immunother Adv       Date:  2021-12-24

9.  TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.

Authors:  Aitor Esparza-Baquer; Ibone Labiano; Omar Sharif; Aloña Agirre-Lizaso; Fiona Oakley; Pedro M Rodrigues; Ekaterina Zhuravleva; Colm J O'Rourke; Elizabeth Hijona; Raul Jimenez-Agüero; Ioana Riaño; Ana Landa; Adelaida La Casta; Marco Y W Zaki; Patricia Munoz-Garrido; Mikel Azkargorta; Felix Elortza; Andrea Vogel; Gernot Schabbauer; Patricia Aspichueta; Jesper B Andersen; Sylvia Knapp; Derek A Mann; Luis Bujanda; Jesus Maria Banales; Maria Jesus Perugorria
Journal:  Gut       Date:  2020-09-09       Impact factor: 23.059

10.  Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

Authors:  Laura Broutier; Gianmarco Mastrogiovanni; Monique Ma Verstegen; Hayley E Francies; Lena Morrill Gavarró; Charles R Bradshaw; George E Allen; Robert Arnes-Benito; Olga Sidorova; Marcia P Gaspersz; Nikitas Georgakopoulos; Bon-Kyoung Koo; Sabine Dietmann; Susan E Davies; Raaj K Praseedom; Ruby Lieshout; Jan N M IJzermans; Stephen J Wigmore; Kourosh Saeb-Parsy; Mathew J Garnett; Luc Jw van der Laan; Meritxell Huch
Journal:  Nat Med       Date:  2017-11-13       Impact factor: 53.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.